Form 4: Clover Health CEO Sells Shares Under 10b5-1 Plan

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 6,823 shares of Class A Common Stock for $2.89 per share under a pre-arranged trading plan.

Summary

• Jamie L. Reynoso, CEO, Medicare Advantage of Clover Health Investments, Corp. (CLOV), reported a sale of company stock.
• The transaction involved 6,823 shares of Class A Common Stock.
• The shares were sold at a weighted average price of $2.89 per share, with prices ranging from $2.86 to $2.93.
• The sale occurred on August 4, 2025.
• This transaction was executed under a Rule 10b5-1 trading plan adopted by Mr. Reynoso on March 13, 2025.
• Following this sale, Mr. Reynoso directly beneficially owns 3,261,485 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled insider stock sale, which is a routine event under a 10b5-1 plan and does not inherently signal a change in company fundamentals or management's long-term view. The number of shares sold is a small fraction of the insider's total holdings.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information.

Negatives

• An insider, the CEO of Medicare Advantage, sold a portion of their holdings.

Risks

• Potential investor perception of insider selling, even if pre-scheduled, could be negative.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret insider selling negatively, though the pre-arranged 10b5-1 plan mitigates the implication of immediate insider sentiment.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan, involving a relatively small number of shares compared to the insider's total holdings. Such a transaction typically does not indicate a material change in the company's outlook or warrant a shift in investment strategy. Investors should monitor broader company performance and market trends rather than reacting to this specific insider transaction.

Keywords

Clover Health, CLOV, Form 4, insider trading, stock sale, Jamie L. Reynoso, 10b5-1 plan, Medicare Advantage